For the latest openings visit the Careers section of our website    CPL Biologicals launches Cadiflu-S, World’s First Virus Like Particle (VLP) Vaccine for Seasonal Influenza
Contract Research Operation
For the latest openings visit the Careers section of our website    CPL Biologicals launches Cadiflu-S, World’s First Virus Like Particle (VLP) Vaccine for Seasonal Influenza

News & Events

  • CPL Biologicals launches Cadiflu-S, World’s First Virus Like Particle (VLP) Vaccine for Seasonal Influenza Read More >>

Contract Research Operation

Cadila Pharmaceuticals Limited has its own Contract Research facility. This Contract Research Organization (CRO), is an independent strategic business unit, located at Dholka in Ahmedabad district at Gujarat, India. The CRO facility offers Pre-clinical and Clinical studies for coherent drug development and caters to over 45 therapeutic areas, including Cardiovascular, Gastrointestinal, Analgesics, Haematinics, Anti-Infectives – Antibiotics, Respiratory, Anti Diabetics and Immunologicals. The CRO is a one stop destination that manages all phases of Contract Research ranging from Pre-clinical, BA – BE & Phase II to Phase IV deploying the strength of local expertise and global technology.

The CRO is a centre of excellence where we enable our clients to accelerate their drug development process deploying abundance of our talent and resources.

Accerediations & Certifications

  • ANVISA certification for the BA/BE centre (since June 2004)
  • ANVISA, Brazil
  • DCGI certification for the BA/BE centre
  • MCC South Africa – Certification for the Dossier submitted
  • Inspected by WHO Geneva
  • MHRA – Dossier submitted and accepted
  • TGA Australia – Dossier submitted and accepted
  • Approved facility by GDF for production of anti-TB drugs
  • Approved BA/BE facility by MoH, UAE

 

www.cro.cadilapharma.com

Counterfeit Drugs : In case of any information on /or availability of counterfeit products...Read More © 2017 Cadila Pharmaceuticals all right reserved
Corporate identification No : U24231GJ1991PLC015132
Cadila Pharmaceuticals